Aptose and Hanmi Enter New Loan Agreement to Advance Development of Tuspetinib in Triplet Therapy for AML

Aptose Biosciences (APS) announced a new US$8.5 million loan agreement with Hanmi Pharmaceutical to support the continued clinical development of tuspetinib (TUS), an oral kinase inhibitor being developed as a frontline triplet therapy for newly diagnosed acute myeloid leukemia (AML). The loan, an uncommitted facility administered through multiple advances, constitutes a related-party transaction, with Aptose relying on a financial hardship exemption. Aptose is currently conducting a Phase 1/2 study of TUS in combination with azacitidine and venetoclax for AML patients ineligible for induction chemotherapy, with early data showing promising antileukemic activity and safety.

Analysis

Aptose Biosciences has secured a new, uncommitted loan facility of up to US$8.5 million from Hanmi Pharmaceutical, a related party, to fund the continued clinical development of its lead drug candidate, tuspetinib (TUS), for newly diagnosed acute myeloid leukemia (AML). This financing is crucial for Aptose, which invoked a financial hardship exemption under MI 61-101 to bypass formal valuation and minority shareholder approval for this related-party transaction, underscoring significant near-term financial constraints and reliance on Hanmi's discretion for fund advances. Despite these challenges, the company reports promising early data from its TUSCANY Phase 1/2 trial, where a TUS-based triplet therapy (TUS+venetoclax+azacitidine) demonstrated safety, complete remissions (CRs), and minimal residual disease (MRD) negativity in AML patients ineligible for induction chemotherapy. Tuspetinib, an oral once-daily agent targeting multiple kinases (SYK, FLT3, KIT, JAK1/2, RSK2) with a favorable toxicity profile, is advancing through trials. While Hanmi's ongoing support is pivotal, forward-looking statements acknowledge material risks, including the ability to negotiate a definitive collaboration agreement with Hanmi and maintaining Nasdaq listing compliance.

Key Decisions for Investors

• Investors should recognize the US$8.5 million uncommitted loan from Hanmi as vital for near-term tuspetinib development, but must closely monitor Aptose's financial condition due to the "financial hardship" basis and the need for further, more substantial funding.
• The encouraging early clinical results for tuspetinib in AML represent a significant potential catalyst; upcoming data from the TUSCANY trial and developments in the Hanmi partnership are key inflection points to scrutinize.
• Carefully evaluate the promising therapeutic profile of tuspetinib against Aptose's pronounced financial vulnerabilities, the discretionary nature of the current funding, and risks related to Nasdaq listing compliance.